Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19 - Evidence Based Medicine on FHIR Implementation Guide v2.0.0-ballot

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Citation: Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19

Active as of 2022-01-10

Generated Narrative: Citation 7638

version: 32; Last updated: 2023-12-02 12:42:05+0000

url: Citation Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19

identifier: FEvIR Object Identifier/7638, Uniform Resource Identifier (URI)/urn:oid:2.16.840.1.113883.4.642.40.44.15.19

version: 2.0.0-ballot

title: Citation for FEvIR Evidence 7637: Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19

status: Active

date: 2022-01-10 13:30:43+0000

publisher: HL7 International / Clinical Decision Support

contact: HL7 International / Clinical Decision Support: http://www.hl7.org/Special/committees/dss

description:

A Evidence Resource to demonstrate complex evidence reporting

UseContexts

Code

Value[x]

UsageContextType program: Program

EBMonFHIR/COKA Demonstration

Citation Classification Type fevir-platform-use: FEvIR Platform Use

Evidence

jurisdiction: World

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

author: Brian S. Alper:

Summaries

Style

Text

Computable Publishing

Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19 [FHIR Resource]. Contributors: Brian S Alper, Harold Lehmann, Ahmad Sofi-Mahmudi, Joanne Dehnbostel, Ilkka Kunnamo [Authors]; Janice Tufte, Vignesh Subbian, Bhagvan Kommadi, Alfonso Iorio, Muhammad Afzal, Kenneth J Wilkins, Surbhi Shah, Amy Price [Reviewers]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 7637. Published August 05, 2021. Created August 05, 2021. Revised August 25, 2021. Available at: https://fevir.net/resources/Evidence/7637. Computable resource at: https://fevir.net/resources/Evidence/7637.

Classifications

Type

Classifier

FEvIR Platform Use

Project Specific

citedArtifact
identifier: FEvIR Object Identifier/7637
relatedIdentifier: https://doi.org/10.1056/NEJMoa2105911
StatusDates
- Activity Actual Period
* Created true 2021-08-05 --> (ongoing)
title
type: Primary title, Human use
language: English
text:
Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill patients with COVID-19

title
type: Different text in an earlier version
language: English
text:
Critically appraised summary of primary outcome of multi-platform RCT of anticoagulation for non-critically ill COVID-19

abstract
type: Description
language: English
text:
Patients who were hospitalized for COVID-19 and who were not critically ill were randomized in a response-adaptive manner to therapeutic-dose anticoagulation with heparin vs. usual-care pharmacologic thromboprophylaxis. The outcome reported here is the effect on organ support-free days (i.e. days without oxygen delivered by high-flow nasal cannula, noninvasive or invasive mechanical ventilation, or the use of vasopressors or inotropes). The statistical result was a median adjusted odds ratio 1.27 (95% credible interval 1.03 to 1.58), based on 1,740 events among 2,219 participants with known outcome out of 2,244 enrolled participants. The probability of superiority of therapeutic-dose anticoagulation with heparin was 98.6%. The risk of bias in this effect estimate is of extremely serious concern based on a serious concern for confounding covariate bias (confounding difference in calendar time), a very serious concern for performance bias (inadequate blinding of intervention deliverers who may determine the outcome based in part on exposure status), and very serious concern for analysis bias (bias related to selection of the analysis, and early trial termination).

abstract
type: Assertion
language: English
text:
It is uncertain whether therapeutic-dose anticoagulation with heparin affects the rate of organ support-free days in hospitalized patients with COVID-19 who are not critically ill.

relatesTo
type: cites
classifier: Journal Article
citation:
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Journal Article]. Contributors: The ATTACC, ACTIV-4a, and REMAP-CAP Investigators. In: The New England Journal of Medicine, DOI 10.1056/NEJMoa2105911. Published August 04, 2021. Available at: https://doi.org/10.1056/NEJMoa2105911.

Documents
- Url
* Citation Anticoagulation for COVID-19 Combined RCTs in NEJM
resourceReference: Identifier: FEvIR Object Identifier/7636
publicationForm
PublishedIns
- Type Title Publisher PublisherLocation
* Database Fast Evidence Interoperability Resources (FEvIR) Platform Computable Publishing LLC Ipswich, MA, USA
articleDate: 2021-08-05
lastRevisionDate: 2021-08-25
language: English
copyright:
https://creativecommons.org/licenses/by-nc-sa/4.0/

webLocation
classifier: Computable resource, JSON
url: https://fevir.net/resources/Evidence/7637
classification
type: Knowledge Artifact Type
classifier: FHIR Resource
classification
type: fhir-resource
classifier: Evidence
contributorship
complete: true
entry
contributor: Practitioner Brian S Alper
forenameInitials: BS
affiliation:
Computable Publishing LLC
Scientific Knowledge Accelerator Foundation
COVID-19 Knowledge Accelerator
contributionType: Conceptualization, Data curation, Investigation, Methodology, Software, Writing - original draft
role: Author/Creator
ContributionInstances
- Type Time
* Risk of bias assessment 2021-08-05
correspondingContact: true
entry
contributor: Practitioner Janice Tufte
affiliation: Hassanah Consulting
contributionType: Writing - review & editing, Formal analysis, Investigation, Validation
role: Reviewer
contributionInstance
type: Reviewed
time: 2021-08-05
contributionInstance
type: Reviewed
time: 2021-08-06
entry
contributor: Practitioner Harold Lehmann
affiliation: Johns Hopkins University
contributionType: Investigation, Methodology, Writing - original draft
role: Author/Creator
entry
contributor: Practitioner Ahmad Sofi-Mahmudi
affiliation: Cochrane Iran Associate Centre
contributionType: Investigation, Methodology, Validation, Writing - review & editing
role: Author/Creator
entry
contributor: Practitioner Joanne Dehnbostel
affiliation: Computable Publishing LLC
contributionType: Project administration, Investigation, Writing - review & editing
role: Author/Creator
entry
contributor: Practitioner Vignesh Subbian
affiliation: University of Arizona
contributionType: Formal analysis, Investigation, Writing - review & editing
role: Reviewer
ContributionInstances
- Type Time
* Reviewed 2021-08-07
entry
contributor: Practitioner Ilkka Kunnamo
affiliation:
Duodecim Medical Publications Ltd., Finland
Scientific Knowledge Accelerator Foundation
contributionType: Writing - review & editing
role: Author/Creator
ContributionInstances
- Type Time
* Reviewed 2021-08-09
entry
contributor: Practitioner Bhagvan Kommadi
affiliation: Value Momentum
contributionType: Methodology, Validation
role: Reviewer
entry
contributor: Practitioner Alfonso Iorio
affiliation: McMaster University
contributionType: Formal analysis, Writing - review & editing
role: Reviewer
entry
contributor: Practitioner Muhammad Afzal
affiliation: Sejong University, Seoul, South Korea
contributionType: Formal analysis, Writing - review & editing
role: Reviewer
entry
contributor: Practitioner Kenneth J Wilkins
affiliation: National Institute of Diabetes & Digestive & Kidney Diseases
contributionType: Formal analysis, Writing - review & editing
role: Reviewer
entry
contributor: Practitioner Surbhi Shah
affiliation: Mayo Clinic Arizona
contributionType: Writing - review & editing, Clinical commentary
role: Reviewer
entry
contributor: Practitioner Amy Price
contributionType: Writing - review & editing
role: Reviewer

Generated Narrative: Practitioner #contributor0

identifier: https://orcid.org//0000-0003-4300-4928
name: Brian S Alper
telecom: balper@computablepublishing.com

Generated Narrative: Practitioner #contributor1

identifier: https://orcid.org//0000-0002-4346-3238
name: Janice Tufte
telecom: hassanahseattle@gmail.com

Generated Narrative: Practitioner #contributor2

name: Harold Lehmann
telecom: lehmann@jhmi.edu

Generated Narrative: Practitioner #contributor3

name: Ahmad Sofi-Mahmudi
telecom: a.sofimahmudi@gmail.com

Generated Narrative: Practitioner #contributor4

name: Joanne Dehnbostel
telecom: jdehnbostel@computablepublishing.com

Generated Narrative: Practitioner #contributor5

name: Vignesh Subbian
telecom: vsubbian@arizona.edu

Generated Narrative: Practitioner #contributor6

identifier: https://orcid.org//0000-0002-4817-6991
name: Ilkka Kunnamo
telecom: ilkka.kunnamo@duodecim.fi

Generated Narrative: Practitioner #contributor7

name: Bhagvan Kommadi
telecom: bhagvanarch@gmail.com

Generated Narrative: Practitioner #contributor8

name: Alfonso Iorio

Generated Narrative: Practitioner #contributor9

name: Muhammad Afzal
telecom: afzalse@gmail.com

Generated Narrative: Practitioner #contributor10

name: Kenneth J Wilkins

Generated Narrative: Practitioner #contributor11

name: Surbhi Shah

Generated Narrative: Practitioner #contributor12

name: Amy Price